Trevi Therapeutics TRVI 深 沪
等待开盘 04-02 09:30:00 美东时间
11.575
-0.355
-2.98%
华盛通- 最 高12.56
- 今 开12.16
- 成交量 86.70万股
- 最 低 11.575
- 昨 收 11.93
- 总市值 14.86亿
- 52周最高 14.39
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.3801
- 委 比 91.39%
- 总股本 1.28亿
- 历史最高 14.39
- 量 比 1.00
- 振 幅 8.26%
- 历史最低 0.46
- 每 手 1
- 风险率 2.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trevi Therapeutics to host investor and analyst day, join healthcare conferences
Trevi Therapeutics to host investor and analyst day, join healthcare conferences Trevi management scheduled to join 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026. Fireside chat set for April 13, 2026 at 12:45 p.m. ET. Company to attend Raymond James 2026 Biotech Innovation Symp
04-01 19:32
Trevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics announced that senior management will participate in several healthcare events in April and May 2026, including virtual and in-person conferences. Haduvio™, Trevi's investigational therapy for chronic cough in IPF, non-IPF ILD, and RCC, has shown significant reduction in cough frequency in clinical trials. The company also plans an Investor & Analyst Day on May 7, 2026, in New York.
04-01 11:30
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright & Co, Stifel, BTIG, Goldman Sachs made changes.
03-18 20:19
Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $22 to $24.
03-18 18:05
Trevi Therapeutics Q4 EPS $(0.06) Beats $(0.10) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 41.18 percent. This is a 45.45 percent increase over losses of $(0.11) per share
03-18 04:09
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Trevi Therapeutics announced alignment with the FDA on its Phase 3 program for treating idiopathic pulmonary fibrosis-related chronic cough, aiming to initiate the first Phase 3 trial in Q2 2026. The company also plans a Phase 2b trial for refractory chronic cough in Q2 2026. Financially, Trevi ended 2025 with $188.3 million in cash, expecting runway into 2028. The company will host a conference call and webcast on March 17, 2026, at 4:30 p.m. ET...
03-17 20:05
Earnings Scheduled For March 17, 2026
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is expected to ...
03-17 19:11
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
03-10 00:28
